For more than 40 years, DiSaia and Creasman Clinical Gynecologic Oncology has been the leading reference for diagnosis and treatment of gynecologic cancers, providing physicians and trainees alike with expert guidance on clinical presentations and management. The fully revised 10th Edition remains the most readable, most comprehensive text in the field. Under outstanding editorial leadership from Dr. William Creasman and featuring a “who’s who” list of expert contributing authors, this authoritative reference is a must-have resource for improving outcomes and providing effective patient care.
1. Introduction - p. 310 2. Anatomy of the breast - p. 311 3. Embryology and development of the breast - p. 313 4. Pregnancy and breast feeding - p. 313 5. Benign breast conditions - p. 313 6. History and physical examination - p. 316 7. Breast imaging - p. 318 8. Breast ultrasound and magnetic resonance imaging - p. 321 9. Diagnostic evaluation - p. 322 10. Epidemiology of breast cancer - p. 324 11. Risk factors and assessment - p. 324 12. Pathology - p. 326 13. Metastases from extramammary tumors - p. 328 14. Biologic markers and prognostic factors - p. 328 15. Staging of breast cancer using the tumor–node–metastasis system - p. 329 16. Treatment of breast cancer - p. 331 17. Special issues - p. 340 18. Conclusions - p. 343 19. Bibliography - p. 344 20. 12. Cancer in pregnancy - p. 344 21. Background and epidemiology of cancer - p. 344 22. The more common solid tumors - p. 346 23. Evaluation and therapeutic modalities - p. 377 24. Hematologic malignancies - p. 393 25. Other tumors - p. 402 26. Bibliography - p. 414 27. 13. Complications of disease and therapy - p. 414 28. 14. Basic principles of chemotherapy and other systemic therapies - p. 442 29. 15. Targeted therapy and molecular genetics - p. 463 30. 16. Molecular hallmarks of cancer - p. 488 31. 17. Immunotherapy in gynecologic malignancies - p. 505 32. 18. Genes and cancer: Genetic counselling and clinical management - p. 520 33. Introduction - p. 520 34. Genetic alterations in cancer - p. 523 35. Mechanisms of human gene mutation - p. 523 36. Cancer epigenetics - p. 528 37. Genomic imprinting and cancer - p. 528 38. Genetic alterations that cause cancer - p. 529 39. Hereditary cancer risk assessment: Genetic counseling and genetic testing - p. 536 40. Genetic counseling and genetic testing for hereditary cancers - p. 551 41. Referral of gynecologic cancer patients for hereditary cancer risk assessment - p. 553 42. Genetic testing - p. 554 43. Legal aspects of genetic testing - p. 555 44. Long-term contact for patients and families with hereditary risk for cancer - p. 556 45. DNA banking - p. 556 46. Conclusion - p. 556 47. Glossary - p. 557 48. Bibliography - p. 559 49. 19. Palliative care and quality of life - p. 559 50. Evolution of palliative care - p. 559 51. Quality of life in gynecologic cancers - p. 561 52. Management of common physical symptoms - p. 566 53. Psychosocial and spiritual needs of patients and families - p. 584 54. Management of psychosocial and spiritual distress - p. 585 55. Quality of life issues in advanced and recurrent ovarian cancer - p. 586 56. Quality of life issues in advanced and recurrent uterine and cervical cancer - p. 588 57. End-of-life decision making - p. 590 58. Bibliography - p. 593 59. 20. Role of minimally invasive surgery in gynecologic malignancies - p. 593 60. 21. Epidemiology of commonly used statistical terms, and analysis of clinical studies - p. 614 61. 22. Basic principles in gynecologic radiotherapy - p. 623 62. Appendix A: Staging - p. 646 63. Appendix B: Modified from common terminology criteria for adverse events (CTCAE) - p. 648 64. Appendix C: Blood component therapy - p. 649 65. Appendix D: Suggested recommendations for routine cancer screening - p. 653 66. Appendix E: Normal nutrition - p. 655 67. Index - p. 660
For more than 40 years, DiSaia and Creasman Clinical Gynecologic Oncology has been the leading reference for diagnosis and treatment of gynecologic cancers, providing physicians and trainees alike with expert guidance on clinical presentations and management. The fully revised 10th Edition remains the most readable, most comprehensive text in the field. Under outstanding editorial leadership from Dr. William Creasman and featuring a “who’s who” list of expert contributing authors, this authoritative reference is a must-have resource for improving outcomes and providing effective patient care.
1. Introduction - p. 310 2. Anatomy of the breast - p. 311 3. Embryology and development of the breast - p. 313 4. Pregnancy and breast feeding - p. 313 5. Benign breast conditions - p. 313 6. History and physical examination - p. 316 7. Breast imaging - p. 318 8. Breast ultrasound and magnetic resonance imaging - p. 321 9. Diagnostic evaluation - p. 322 10. Epidemiology of breast cancer - p. 324 11. Risk factors and assessment - p. 324 12. Pathology - p. 326 13. Metastases from extramammary tumors - p. 328 14. Biologic markers and prognostic factors - p. 328 15. Staging of breast cancer using the tumor–node–metastasis system - p. 329 16. Treatment of breast cancer - p. 331 17. Special issues - p. 340 18. Conclusions - p. 343 19. Bibliography - p. 344 20. 12. Cancer in pregnancy - p. 344 21. Background and epidemiology of cancer - p. 344 22. The more common solid tumors - p. 346 23. Evaluation and therapeutic modalities - p. 377 24. Hematologic malignancies - p. 393 25. Other tumors - p. 402 26. Bibliography - p. 414 27. 13. Complications of disease and therapy - p. 414 28. 14. Basic principles of chemotherapy and other systemic therapies - p. 442 29. 15. Targeted therapy and molecular genetics - p. 463 30. 16. Molecular hallmarks of cancer - p. 488 31. 17. Immunotherapy in gynecologic malignancies - p. 505 32. 18. Genes and cancer: Genetic counselling and clinical management - p. 520 33. Introduction - p. 520 34. Genetic alterations in cancer - p. 523 35. Mechanisms of human gene mutation - p. 523 36. Cancer epigenetics - p. 528 37. Genomic imprinting and cancer - p. 528 38. Genetic alterations that cause cancer - p. 529 39. Hereditary cancer risk assessment: Genetic counseling and genetic testing - p. 536 40. Genetic counseling and genetic testing for hereditary cancers - p. 551 41. Referral of gynecologic cancer patients for hereditary cancer risk assessment - p. 553 42. Genetic testing - p. 554 43. Legal aspects of genetic testing - p. 555 44. Long-term contact for patients and families with hereditary risk for cancer - p. 556 45. DNA banking - p. 556 46. Conclusion - p. 556 47. Glossary - p. 557 48. Bibliography - p. 559 49. 19. Palliative care and quality of life - p. 559 50. Evolution of palliative care - p. 559 51. Quality of life in gynecologic cancers - p. 561 52. Management of common physical symptoms - p. 566 53. Psychosocial and spiritual needs of patients and families - p. 584 54. Management of psychosocial and spiritual distress - p. 585 55. Quality of life issues in advanced and recurrent ovarian cancer - p. 586 56. Quality of life issues in advanced and recurrent uterine and cervical cancer - p. 588 57. End-of-life decision making - p. 590 58. Bibliography - p. 593 59. 20. Role of minimally invasive surgery in gynecologic malignancies - p. 593 60. 21. Epidemiology of commonly used statistical terms, and analysis of clinical studies - p. 614 61. 22. Basic principles in gynecologic radiotherapy - p. 623 62. Appendix A: Staging - p. 646 63. Appendix B: Modified from common terminology criteria for adverse events (CTCAE) - p. 648 64. Appendix C: Blood component therapy - p. 649 65. Appendix D: Suggested recommendations for routine cancer screening - p. 653 66. Appendix E: Normal nutrition - p. 655 67. Index - p. 660
